Johnson & Johnson Innovative Medicine — Additions to Property, Plant & Equipment increased by 16.5% to $479.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $418.00M to $479.00M. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — Additions to Property, Plant & Equipment shows an upward trend with a 11.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher spending indicates investment in future production capacity or research capabilities, signaling growth expectations.
This metric tracks the capital expenditures made to acquire or improve physical assets, such as manufacturing facilities...
Comparable to 'Capital Expenditures' (CapEx) reported by peers for their pharmaceutical manufacturing and R&D divisions.
jnj_segment_innovative_medicine_additions_to_property_plant_equipment| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $343.50M | $343.50M | $343.50M | $343.50M | $413.25M | $413.25M | $413.25M | $413.25M | $232.00M | $321.00M | $418.00M | $739.00M | $276.00M | $411.00M | $479.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +20.3% | +0.0% | +0.0% | +0.0% | -43.9% | +38.4% | +30.2% | +76.8% | -62.7% | +48.9% | +16.5% |
| YoY Change | — | — | — | — | +20.3% | +20.3% | +20.3% | +20.3% | -43.9% | -22.3% | +1.1% | +78.8% | +19.0% | +28.0% | +14.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.